QuidelOrtho
Runs hospital lab instruments and point-of-care rapid tests under one roof.
Something off on this page? Send us feedback.
Profile
Pairs a central-lab reagents-and-instruments franchise built around VITROS chemistry and immunoassay analyzers with a point-of-care rapid-test line built around Sofia and QuickVue, plus smaller immunohematology and molecular-testing units, selling mostly on recurring reagents and service contracts.
Two diagnostics franchises sit under one roof: a central-lab business selling VITROS chemistry and immunoassay analyzers with the reagents and service contracts that keep them running, and a point-of-care line built around the Sofia analyzer and QuickVue rapid tests for clinics and home use. A transfusion-medicine unit and a smaller molecular line round out the portfolio.
The lab business is the largest and steadiest, anchored in recurring reagents; point-of-care swings with flu and respiratory demand. Hospitals, reference labs, and blood banks across North America, Europe, and China make up most sales.
Respiratory testing is a shrinking share of revenue after the pandemic surge. US donor-screening is winding down, one molecular platform is being retired for an acquired successor, and a blood-products joint arrangement ended in early 2026. Leadership turned over after a 2024 guidance shortfall. Predecessor Quidel traces to 1979.
Company facts
Key statistics
Year to date −48.8% · Average volume (30d) 1.5M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| May 7, 2026 | UBS | Target | $17 | $12 | ||
| May 7, 2026 | Jefferies | Downgrade | Buy | Hold | $12.50 | |
| Apr 10, 2026 | UBS | Reiterate | Neutral | $30 | $17 | |
| Feb 12, 2026 | UBS | Target | $35 | $30 | ||
| Jan 21, 2026 | UBS | Reiterate | Neutral | $50 | $35 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | −$0.05 | $0.13 | +366.2% | $618.7M | $630.9M | +2.0% | −24.69% |
| May 5, 2026Q1 FY26 | $0.37 | −$0.04 | −110.8% | $665.2M | $619.8M | −6.8% | −6.00% |
| Feb 11, 2026Q4 FY25 | $0.43 | $0.46 | +7.0% | $700.7M | $723.6M | +3.3% | −17.57% |
| Nov 5, 2025Q3 FY25 | $0.51 | $0.80 | +56.9% | $700.2M | $699.9M | 0.0% | −22.32% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $692.8M | $613.9M | $699.9M | $723.6M | $619.8M | $630.9M | |
| Gross profit | $343.3M | $274.9M | $335.6M | $320.4M | $263.8M | $272.9M | |
| Operating income | $32.6M | −$180.7M | −$704.8M | −$66.3M | −$27.4M | −$21.8M | |
| Net income | −$12.7M | −$255.4M | −$733.0M | −$130.7M | −$91.8M | −$92.9M | |
| Diluted EPS | −$0.19 | −$3.77 | −$10.78 | −$1.95 | −$1.35 | −$1.36 | |
| Gross margin | 49.6% | 44.8% | 47.9% | 44.3% | 42.6% | 43.3% | |
| Operating margin | 4.7% | -29.4% | -100.7% | -9.2% | -4.4% | -3.5% |
Fiscal years (4-quarter sums)FY21 $1.70B · FY22 $3.27B · FY23 $3.00B · FY24 $2.78B · FY25 $2.73B
Revenue by geography · Q2 FY26
Balance sheet, Jun 28, 2026Cash & short-term investments $123.4M · Total debt $3.08B · Total assets $5.72B · Shareholders' equity $1.77B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 68.19M · Float 67.38M · 98.8% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 11.20M | 16.43% | 13F | Aug 7, 2026 |
| FMR LLC | 7.36M | 10.80% | 13F | Aug 13, 2026 |
| Newtyn Management, LLC | 6.63M | 9.72% | 13F | Aug 14, 2026 |
| Capital Management LP | 4.20M | 6.25% | 13G | Nov 13, 2024 |
| Vanguard Portfolio Management LLC | 4.14M | 6.06% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Feb 13, 2026 | Brian J. Blaser | officer: President and CEO | +10,540 | $23.59 |
| Feb 13, 2026 | Joseph M. Busky | officer: Chief Financial Officer | +3,370 | $23.66 |
| Feb 13, 2026 | Matthew Strobeck | director | +10,000 | $23.96 |
| Dec 10, 2025 | Ann D. Rhoads | director | +750 | $28.28 |
| Nov 26, 2025 | Joseph D. Jr. Wilkins | director | +370 | $27.96 |
Peers
- Abbott
Broadest head-to-head across labs, point-of-care, cardiac, and molecular.
- Danaher
Beckman Coulter and Cepheid combine for a two-front lab and molecular rival.
- Bio-Rad Laboratories
IH-1000 is the direct gel-card rival to ORTHO VISION in immunohematology.
- Grifols (ADR)
Direct transfusion-medicine rival since the 2026 joint-business exit.
- BD
BD Veritor contests rapid antigen point-of-care testing head-to-head.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| QuidelOrtho | $14.70 | −0.27% | $1.01B | — | 17.5 | 0.4 | +2.6% |
| Abbott | $112.20 | −0.22% | $194.62B | 36.2 | 19.4 | 4.2 | +13.0% |
| Danaher | $215.50 | −0.25% | $151.89B | 38.4 | 24.3 | 6.0 | +5.5% |
| Bio-Rad Laboratories | $387.70 | +0.02% | $10.44B | 47.0 | 37.6 | 4.0 | −0.1% |
| Grifols (ADR) | $7.69 | 0.00% | $6.51B | 9.9 | — | 0.9 | −4.2% |
| BD | $189.00 | −0.27% | $52.22B | 57.1 | 14.3 | 2.5 | −9.6% |
| Median | 38.4 | 21.8 | 4.0 | −0.1% |